Histone deacetylases (HDAC) in physiological and pathological bone remodelling

M. D. Cantley, A. C W Zannettino, P. M. Bartold, D. P. Fairlie, D. R. Haynes

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Histone deacetylases (HDACs)2 play important roles in the epigenetic regulation of gene expression in cells and are emerging therapeutic targets for treating a wide range of diseases. HDAC inhibitors (HDACi)3 that act on multiple HDAC enzymes have been used clinically to treat a number of solid and hematological malignancies. HDACi are also currently being studied for their efficacy in non-malignant diseases, including pathologic bone loss, but this has necessitated a better understanding of the roles of individual HDAC enzymes, particularly the eleven zinc-containing isozymes. Selective isozyme-specific inhibitors currently being developed against class I HDACs (1, 2, 3 and 8) and class II HDACs (4, 5, 6, 7, 9 and 10) will be valuable tools for elucidating the roles played by individual HDACs in different physiological and pathological settings. Isozyme-specific HDACi promise to have greater efficacy and reduced side effects, as required for treating chronic disease over extended periods of time. This article reviews the current understanding of roles for individual HDAC isozymes and effects of HDACi on bone cells, (osteoblasts, osteoclasts and osteocytes), in relation to bone remodelling in conditions characterised by pathological bone loss, including periodontitis, rheumatoid arthritis and myeloma bone disease.

LanguageEnglish
Pages162-174
Number of pages13
JournalBone
Volume95
DOIs
Publication statusPublished - 1 Feb 2017

Keywords

  • Histone deacetylases (HDAC)
  • Myeloma bone disease
  • Osteoblasts
  • Osteoclasts
  • Periodontitis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Cantley, M. D., Zannettino, A. C. W., Bartold, P. M., Fairlie, D. P., & Haynes, D. R. (2017). Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone, 95, 162-174. https://doi.org/10.1016/j.bone.2016.11.028
Cantley, M. D. ; Zannettino, A. C W ; Bartold, P. M. ; Fairlie, D. P. ; Haynes, D. R. / Histone deacetylases (HDAC) in physiological and pathological bone remodelling. In: Bone. 2017 ; Vol. 95. pp. 162-174.
@article{80da139753734bd682feb8fe9fd9e335,
title = "Histone deacetylases (HDAC) in physiological and pathological bone remodelling",
abstract = "Histone deacetylases (HDACs)2 play important roles in the epigenetic regulation of gene expression in cells and are emerging therapeutic targets for treating a wide range of diseases. HDAC inhibitors (HDACi)3 that act on multiple HDAC enzymes have been used clinically to treat a number of solid and hematological malignancies. HDACi are also currently being studied for their efficacy in non-malignant diseases, including pathologic bone loss, but this has necessitated a better understanding of the roles of individual HDAC enzymes, particularly the eleven zinc-containing isozymes. Selective isozyme-specific inhibitors currently being developed against class I HDACs (1, 2, 3 and 8) and class II HDACs (4, 5, 6, 7, 9 and 10) will be valuable tools for elucidating the roles played by individual HDACs in different physiological and pathological settings. Isozyme-specific HDACi promise to have greater efficacy and reduced side effects, as required for treating chronic disease over extended periods of time. This article reviews the current understanding of roles for individual HDAC isozymes and effects of HDACi on bone cells, (osteoblasts, osteoclasts and osteocytes), in relation to bone remodelling in conditions characterised by pathological bone loss, including periodontitis, rheumatoid arthritis and myeloma bone disease.",
keywords = "Histone deacetylases (HDAC), Myeloma bone disease, Osteoblasts, Osteoclasts, Periodontitis, Rheumatoid arthritis",
author = "Cantley, {M. D.} and Zannettino, {A. C W} and Bartold, {P. M.} and Fairlie, {D. P.} and Haynes, {D. R.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.bone.2016.11.028",
language = "English",
volume = "95",
pages = "162--174",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

Cantley, MD, Zannettino, ACW, Bartold, PM, Fairlie, DP & Haynes, DR 2017, 'Histone deacetylases (HDAC) in physiological and pathological bone remodelling', Bone, vol. 95, pp. 162-174. https://doi.org/10.1016/j.bone.2016.11.028

Histone deacetylases (HDAC) in physiological and pathological bone remodelling. / Cantley, M. D.; Zannettino, A. C W; Bartold, P. M.; Fairlie, D. P.; Haynes, D. R.

In: Bone, Vol. 95, 01.02.2017, p. 162-174.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Histone deacetylases (HDAC) in physiological and pathological bone remodelling

AU - Cantley, M. D.

AU - Zannettino, A. C W

AU - Bartold, P. M.

AU - Fairlie, D. P.

AU - Haynes, D. R.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Histone deacetylases (HDACs)2 play important roles in the epigenetic regulation of gene expression in cells and are emerging therapeutic targets for treating a wide range of diseases. HDAC inhibitors (HDACi)3 that act on multiple HDAC enzymes have been used clinically to treat a number of solid and hematological malignancies. HDACi are also currently being studied for their efficacy in non-malignant diseases, including pathologic bone loss, but this has necessitated a better understanding of the roles of individual HDAC enzymes, particularly the eleven zinc-containing isozymes. Selective isozyme-specific inhibitors currently being developed against class I HDACs (1, 2, 3 and 8) and class II HDACs (4, 5, 6, 7, 9 and 10) will be valuable tools for elucidating the roles played by individual HDACs in different physiological and pathological settings. Isozyme-specific HDACi promise to have greater efficacy and reduced side effects, as required for treating chronic disease over extended periods of time. This article reviews the current understanding of roles for individual HDAC isozymes and effects of HDACi on bone cells, (osteoblasts, osteoclasts and osteocytes), in relation to bone remodelling in conditions characterised by pathological bone loss, including periodontitis, rheumatoid arthritis and myeloma bone disease.

AB - Histone deacetylases (HDACs)2 play important roles in the epigenetic regulation of gene expression in cells and are emerging therapeutic targets for treating a wide range of diseases. HDAC inhibitors (HDACi)3 that act on multiple HDAC enzymes have been used clinically to treat a number of solid and hematological malignancies. HDACi are also currently being studied for their efficacy in non-malignant diseases, including pathologic bone loss, but this has necessitated a better understanding of the roles of individual HDAC enzymes, particularly the eleven zinc-containing isozymes. Selective isozyme-specific inhibitors currently being developed against class I HDACs (1, 2, 3 and 8) and class II HDACs (4, 5, 6, 7, 9 and 10) will be valuable tools for elucidating the roles played by individual HDACs in different physiological and pathological settings. Isozyme-specific HDACi promise to have greater efficacy and reduced side effects, as required for treating chronic disease over extended periods of time. This article reviews the current understanding of roles for individual HDAC isozymes and effects of HDACi on bone cells, (osteoblasts, osteoclasts and osteocytes), in relation to bone remodelling in conditions characterised by pathological bone loss, including periodontitis, rheumatoid arthritis and myeloma bone disease.

KW - Histone deacetylases (HDAC)

KW - Myeloma bone disease

KW - Osteoblasts

KW - Osteoclasts

KW - Periodontitis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85002950435&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2016.11.028

DO - 10.1016/j.bone.2016.11.028

M3 - Review article

VL - 95

SP - 162

EP - 174

JO - Bone

T2 - Bone

JF - Bone

SN - 8756-3282

ER -

Cantley MD, Zannettino ACW, Bartold PM, Fairlie DP, Haynes DR. Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone. 2017 Feb 1;95:162-174. https://doi.org/10.1016/j.bone.2016.11.028